No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease

Justin Tao Wen Chiam; Katie Lunnon; Nicola Voyle; Petra Proitsi; Giovanni Coppola; Daniel Geschwind; Sally Nelson; Caroline Johnston; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Angela Hodges; Simon Lovestone; Stephen Newhouse; Richard James Butler Dobson; Steven John Kiddle; Martina Sattlecker

doi:10.3233/JAD-150289

No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease

Justin Tao Wen Chiam, Katie Lunnon, Nicola Voyle, Petra Proitsi, Giovanni Coppola, Daniel Geschwind, Sally Nelson, Caroline Johnston, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Angela Hodges, Simon Lovestone, Stephen Newhouse, Richard James Butler Dobson, Steven John Kiddle, Martina Sattlecker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

356 Downloads (Pure)

Abstract

BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.

OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.

METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.

RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.

CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.

Original language	English
Pages (from-to)	741-750
Number of pages	10
Journal	JOURNAL OF ALZHEIMERS DISEASE
Volume	47
Issue number	3
DOIs	https://doi.org/10.3233/JAD-150289
Publication status	Published - 3 Aug 2015

Keywords

Aged
Alzheimer Disease
Apolipoprotein E4
Biomarkers
Cholinesterase Inhibitors
Cognitive Dysfunction
Cohort Studies
Female
Gene Expression
Humans
Male
Mental Status Schedule
Microarray Analysis
Nootropic Agents
Proteomics
Reproducibility of Results
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

10.3233/JAD-150289

No evidence to suggest_CHIAM_Accepted9May2015_GREEN AAMAccepted author manuscript, 2.69 MB

Cite this

Chiam, J. T. W., Lunnon, K., Voyle, N., Proitsi, P., Coppola, G., Geschwind, D., Nelson, S., Johnston, C., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Hodges, A., Lovestone, S., Newhouse, S., Dobson, R. J. B., Kiddle, S. J., & Sattlecker, M. (2015). No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. JOURNAL OF ALZHEIMERS DISEASE, 47(3), 741-750. https://doi.org/10.3233/JAD-150289

@article{c2589eb085824213bce140587d40a074,

title = "No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease",

abstract = "BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.",

keywords = "Aged, Alzheimer Disease, Apolipoprotein E4, Biomarkers, Cholinesterase Inhibitors, Cognitive Dysfunction, Cohort Studies, Female, Gene Expression, Humans, Male, Mental Status Schedule, Microarray Analysis, Nootropic Agents, Proteomics, Reproducibility of Results, Journal Article, Research Support, Non-U.S. Gov't",

author = "Chiam, {Justin Tao Wen} and Katie Lunnon and Nicola Voyle and Petra Proitsi and Giovanni Coppola and Daniel Geschwind and Sally Nelson and Caroline Johnston and Hilkka Soininen and Iwona K{\l}oszewska and Patrizia Mecocci and Magda Tsolaki and Bruno Vellas and Angela Hodges and Simon Lovestone and Stephen Newhouse and Dobson, {Richard James Butler} and Kiddle, {Steven John} and Martina Sattlecker",

year = "2015",

month = aug,

day = "3",

doi = "10.3233/JAD-150289",

language = "English",

volume = "47",

pages = "741--750",

journal = "JOURNAL OF ALZHEIMERS DISEASE",

issn = "1387-2877",

publisher = "IOS Press BV",

number = "3",

}

Chiam, JTW, Lunnon, K, Voyle, N , Proitsi, P, Coppola, G, Geschwind, D, Nelson, S, Johnston, C, Soininen, H, Kłoszewska, I, Mecocci, P, Tsolaki, M, Vellas, B, Hodges, A , Lovestone, S , Newhouse, S , Dobson, RJB , Kiddle, SJ & Sattlecker, M 2015, 'No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease', JOURNAL OF ALZHEIMERS DISEASE, vol. 47, no. 3, pp. 741-750. https://doi.org/10.3233/JAD-150289

TY - JOUR

T1 - No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease

AU - Chiam, Justin Tao Wen

AU - Lunnon, Katie

AU - Voyle, Nicola

AU - Proitsi, Petra

AU - Coppola, Giovanni

AU - Geschwind, Daniel

AU - Nelson, Sally

AU - Johnston, Caroline

AU - Soininen, Hilkka

AU - Kłoszewska, Iwona

AU - Mecocci, Patrizia

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Hodges, Angela

AU - Lovestone, Simon

AU - Newhouse, Stephen

AU - Dobson, Richard James Butler

AU - Kiddle, Steven John

AU - Sattlecker, Martina

PY - 2015/8/3

Y1 - 2015/8/3

N2 - BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.

AB - BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.

KW - Aged

KW - Alzheimer Disease

KW - Apolipoprotein E4

KW - Biomarkers

KW - Cholinesterase Inhibitors

KW - Cognitive Dysfunction

KW - Cohort Studies

KW - Female

KW - Gene Expression

KW - Humans

KW - Male

KW - Mental Status Schedule

KW - Microarray Analysis

KW - Nootropic Agents

KW - Proteomics

KW - Reproducibility of Results

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

UR - http://www.scopus.com/inward/record.url?scp=84938701203&partnerID=8YFLogxK

U2 - 10.3233/JAD-150289

DO - 10.3233/JAD-150289

M3 - Article

C2 - 26401708

AN - SCOPUS:84938701203

SN - 1387-2877

VL - 47

SP - 741

EP - 750

JO - JOURNAL OF ALZHEIMERS DISEASE

JF - JOURNAL OF ALZHEIMERS DISEASE

IS - 3

ER -

No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease

Abstract

Keywords

Access to Document

Other files and links

Cite this